Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China.

ABSTRACT:

Objective

The ASTRUM-005 trial demonstrated that adding serplulimab to chemotherapy significantly prolonged the survival of patients with extensive-stage small cell lung cancer (SCLC), but also increased the risk of adverse events. Given the high cost of serplulimab compared to chemotherapy, this study aimed to evaluate the cost-effectiveness of serplulimab plus chemotherapy as a first-line treatment for extensive-stage SCLC from the perspective of China's healthcare system.

Methods

A Markov model was developed to simulate the disease process of extensive-stage SCLC and estimate the health outcomes and direct medical costs of patients. Scenario analyses, univariate sensitivity analyses, and probabilistic sensitivity analyses were conducted to explore the impact of different

SUBMITTER: Xiang G 

PROVIDER: S-EPMC10501445 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature